PALI vs. HYPD, ALGS, ICCC, DRRX, ACRV, GNTA, SKYE, TELO, CUE, and TLPH
Should you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include Hyperion DeFi (HYPD), Aligos Therapeutics (ALGS), ImmuCell (ICCC), DURECT (DRRX), Acrivon Therapeutics (ACRV), Genenta Science (GNTA), Skye Bioscience (SKYE), Telomir Pharmaceuticals (TELO), Cue Biopharma (CUE), and Talphera (TLPH). These companies are all part of the "pharmaceutical products" industry.
Palisade Bio vs. Its Competitors
Palisade Bio (NASDAQ:PALI) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.
Palisade Bio has higher revenue and earnings than Hyperion DeFi. Palisade Bio is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.
Palisade Bio has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Hyperion DeFi has a beta of 2.57, meaning that its share price is 157% more volatile than the S&P 500.
11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are held by institutional investors. 0.7% of Palisade Bio shares are held by company insiders. Comparatively, 10.9% of Hyperion DeFi shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Palisade Bio presently has a consensus price target of $12.00, suggesting a potential upside of 548.65%. Hyperion DeFi has a consensus price target of $2.00, suggesting a potential downside of 75.28%. Given Palisade Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Palisade Bio is more favorable than Hyperion DeFi.
In the previous week, Palisade Bio had 4 more articles in the media than Hyperion DeFi. MarketBeat recorded 7 mentions for Palisade Bio and 3 mentions for Hyperion DeFi. Hyperion DeFi's average media sentiment score of 0.83 beat Palisade Bio's score of 0.45 indicating that Hyperion DeFi is being referred to more favorably in the news media.
Palisade Bio has a net margin of 0.00% compared to Hyperion DeFi's net margin of -62,238.41%. Palisade Bio's return on equity of -214.94% beat Hyperion DeFi's return on equity.
Summary
Palisade Bio beats Hyperion DeFi on 10 of the 16 factors compared between the two stocks.
Get Palisade Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Palisade Bio Competitors List
Related Companies and Tools
This page (NASDAQ:PALI) was last updated on 10/15/2025 by MarketBeat.com Staff
